$599

URLi ISRs Could Sting LLY; Ph3 Results Mixed

Lilly presented results from its two ultra-rapid-acting lispro (URLi) pivotal trials, PRONTO-T1D and PRONTO-T2D. Below, FENIX provides an overview of the data as well as thoughts on the imbalance in injection site reactions (ISRs) with URLi and the potential market implications.

This content is for Read Less members only.
Register
Already a member? Log in here